Atara Biotherapeutics, Inc. - Common Stock (ATRA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
ATRA on Nasdaq
Shares outstanding
7,230,838
Price per share
$17.86
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
1,883,136
Total reported value
$26,983,314
% of total 13F portfolios
0%
Share change
+79,762
Value change
+$1,944,887
Number of holders
36
Price from insider filings
$17.86
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atara Biotherapeutics, Inc. - Common Stock (ATRA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% 0% $10,764,875 +$659,400 751,223 +6.5% Redmile Group, LLC 12 Nov 2025
EcoR1 Capital, LLC 9.9% $10,258,030 715,853 EcoR1 Capital, LLC 30 Sep 2025
Panacea Innovation Ltd 9.5% $4,180,000 550,000 Panacea Venture Healthcare Fund II, L.P. 30 Jan 2025

As of 30 Sep 2025, 36 institutional investors reported holding 1,883,136 shares of Atara Biotherapeutics, Inc. - Common Stock (ATRA). This represents 26% of the company’s total 7,230,838 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
EcoR1 Capital, LLC 7.9% 573,183 0% 0.39% $8,213,712
Redmile Group, LLC 6.1% 441,701 0% 0.62% $6,329,575
VANGUARD GROUP INC 2.8% 203,438 +6.6% 0% $2,915,266
MARSHALL WACE, LLP 1.6% 115,796 +173% 0% $1,659,357
BlackRock, Inc. 0.97% 69,833 -1.4% 0% $1,000,706
MACKENZIE FINANCIAL CORP 0.88% 63,816 +183% 0% $914,483
GEODE CAPITAL MANAGEMENT, LLC 0.84% 60,526 +0.65% 0% $867,499
ACADIAN ASSET MANAGEMENT LLC 0.78% 56,416 -13% 0% $807,000
STALEY CAPITAL ADVISERS INC 0.69% 50,000 -33% 0.03% $716,500
MORGAN STANLEY 0.5% 35,938 +141% 0% $514,991
GSA CAPITAL PARTNERS LLP 0.36% 26,213 +34% 0.03% $376,000
STATE STREET CORP 0.35% 25,253 0% 0% $361,875
JANE STREET GROUP, LLC 0.31% 22,060 0% $316,120
RENAISSANCE TECHNOLOGIES LLC 0.26% 18,936 +12% 0% $271,353
UBS Group AG 0.24% 17,268 +106% 0% $247,451
FMR LLC 0.24% 17,156 0% 0% $245,845
Cambridge Investment Research Advisors, Inc. 0.24% 17,109 0% $245,000
Quadrature Capital Ltd 0.23% 16,542 0% $236,881
GLOBEFLEX CAPITAL L P 0.21% 15,458 0.03% $221,513
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.19% 14,000 0% 0% $200,620
NORTHERN TRUST CORP 0.15% 11,033 -1.2% 0% $158,103
BANK OF AMERICA CORP /DE/ 0.08% 5,845 -24% 0% $83,758
SBI Securities Co., Ltd. 0.02% 1,404 0% 0% $20,119
ROYAL BANK OF CANADA 0.02% 1,209 -17% 0% $17,000
Private Wealth Asset Management, LLC 0.01% 900 0% $12,897

Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 1,883,136 $26,983,314 +$1,944,887 $14.33 36
2025 Q2 1,803,350 $13,921,685 -$1,938,164 $7.72 32
2025 Q1 2,086,793 $12,393,904 -$4,023,428 $5.94 36
2024 Q4 2,368,286 $31,519,295 -$410,987 $13.31 41
2024 Q3 2,414,500 $19,628,975 -$1,762,796 $8.13 33
2024 Q2 2,653,675 $22,554,322 +$22,225,788 $8.50 43